Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

"A medication can be more effective and just as safe," the ad maintains. AstraZeneca cites FDA's response to safety reviewer's claim that Crestor is one of five drugs with unresolved safety issues.

You may also be interested in...



Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety

AstraZeneca's newspaper ads and website contain "false and/or misleading statements about the FDA's current opinion about Crestor," Public Citizen says in letter to Acting Commissioner Crawford. Agency is urged to stop the company's advertising campaign.

Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety

AstraZeneca's newspaper ads and website contain "false and/or misleading statements about the FDA's current opinion about Crestor," Public Citizen says in letter to Acting Commissioner Crawford. Agency is urged to stop the company's advertising campaign.

Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer

FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel